HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc. (NASDAQ: IPXL) held its 2010 Annual Meeting of Stockholders today in San Mateo, California. Impax stockholders elected to a one-year term each of the seven nominees for director named in the Company’s proxy statement, approved the amendment of the Company's Amended and Restated 2002 Equity Incentive Plan and ratified the appointment of Grant Thornton LLP as independent auditors for the fiscal year ending December 31, 2010.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.
Impax Laboratories, Inc.
Sr. Director, Investor Relations and Corporate Communications
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical